Acute Lymphoblastic Leukemia Clinical Trial
Official title:
Study of the Biology and Natural History of Disease Outcomes in Patients Treated With Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies
Verified date | May 2018 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Background:
Allogeneic hematopoietic stem cell transplantation (or allotransplant; donor blood stem
cells) have been used with varying degrees of success as an immune therapy for blood-system
cancers (leukemias, myelodysplastic syndrome, lymphomas, multiple myeloma, etc.). Some people
s cancer remains active (comes back or continues to spread) after an allotransplant, while
other peoples cancer disappears and they are hopefully cured. National Institutes of Health
(NIH) researchers are studying the reasons for these different treatment outcomes, and trying
to develop better cancer treatments for people with active cancer after allotransplant.
Researchers are collecting data from people who have had allotransplants for a cancer of the
blood, whether or not the cancer is in remission, and from their donors. Those with active
cancers may be eligible to participate in one of several NIH studies testing treatments for
active cancer after allotransplant.
Objectives:
- To develop a systematic, comprehensive evaluation of individuals with relapsed malignant
blood cancers after allotransplant (and, if available, their donors) to identify
potential treatment study options
- To compare the immune system after allotransplant between people whose cancers are
growing with people whose cancers remain in remission.
- To compare the immune system after cancer relapse/progression treatment between people
whose cancer responds to treatment with those whose cancers continue to grow.
Eligibility:
- Individuals whose blood system cancer grows or comes back after receiving allotransplant
treatment.
- Individuals whose blood system cancer is responding or in remission 100 days or more
after receiving allotransplant treatment.
- Related stem-cell donors of eligible allotransplant recipients.
Design:
- Participants will be evaluated with a full physical examination, detailed medical
history (for recipients, including a history of allotransplant treatment process,
side-effects, etc.), and blood tests. Recipients will also have imaging studies,
possible tissue biopsies, quality of life questionnaires/assessments, and other tests to
evaluate the current state of their cancer, whether active or in remission. In some
cases, it may be possible to substitute results from recent tests and/or biopsies.
- Healthy related donors will have apheresis to provide white blood cells for study and/or
for use in potential treatment options. If stem cells would be medically helpful to a
recipient, their donors might be asked to take injections of filgrastim before the
apheresis procedure to stimulate the production of stem cells for collection.
- As feasible, all recipients will be asked to return to the NIH for detailed follow-up
visits in conjunction with 6, 12, and 24 months post-allotransplant evaluations, and may
be monitored between visits.
- Recipients whose cancers are active and who are found to be eligible for treatment
protocols at the NIH will continue to be monitored on this study while participating on
treatment protocols. Return visits and follow-up tests for this study will be
coordinated with those required by the treatment protocol.
- Participants may return in the future to be evaluated for new treatment study options
(recipients) or additional cell donations for therapy (donors).
Status | Terminated |
Enrollment | 56 |
Est. completion date | July 14, 2017 |
Est. primary completion date | June 28, 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 99 Years |
Eligibility |
- INCLUSION CRITERIA: RECIPIENT SUBJECTS: 1. Individuals who are candidates for allotransplant therapy for hematologic malignancies and are being evaluated at the Clinical Center for planned allotransplantation. 2. Individuals who have received allotransplant treatment for hematologic malignancy and have: 1. Hematologic recovery after allotransplant: e.g., have had neutrophil recovery to 500 cells/mcL. Secondary cytopenias or cytopenias due to disease progression will be permitted. Note: this requirement will not apply to subjects enrolling pre-transplant, i.e, who receive transplant-related medical care at the Clinical Center (CC). 2. An ongoing relationship with a primary oncologist who will continue to provide continuity of care during and after study participation. 3. Following record review and information exchange between the patients primary oncologist and the National Cancer Institute (NCI) Principal Investigator (PI)/Designee, the PI/Designee determines that the individual reasonably could be expected to safely tolerate travel to and from the Clinical Center (CC) to undergo evaluation as defined in the protocol, in the event that the patient is ineligible or uninterested in participating in open treatment protocols. 3. 18-99 years. 4. Ability of subject to understand and the willingness to sign a written informed consent document. DONOR SUBJECTS: 1. Individuals who are/will be the donors of allogeneic hematopoietic stem cell transplants received by Recipient-Subjects who are to be enrolled on this protocol. 2. Age 18-99 years. 3. Ability of the subject to understand and the willingness to sign a written informed consent document. 4. Individuals with evidence of infection with transfusion-transmittable agents (Hepatitis B and C Viruses (HBV, HCV); Human Immunodeficiency Virus (HIV (Omega)), Human TLymphotrophic Virus (HTLV I/II), West Nile Virus (WNV) and Trypanosoma cruzi) will not be excluded from study participation. However, Donor-Subjects with evidence of HIV infection will only be able to donate cells for research. Donors with a history of HBV or HCV infection will be able to donate for research, and may be eligible to donate for therapeutic administration. However, determination of permissibility for clinical donation will require a hepatology consultation and the consent of the intended recipient after discussion of the risk/benefit of the donor cell product and the possibility/consequences of transmission. The PI/Designee will make the final determination of permissibility of donation for recipient cell therapy. 6. Unrelated donor selection will be in accordance with the National Marrow Donor Program (NMDP) standards. When a potentially eligible recipient of an unrelated donor product from an NMDP Center is identified, the recipient will complete an NMDP search transfer request to allow NIH NMDP staff to contact the NMDP Coordinating Center, who will, in turn, contact the donors prior Donor Center. The NMDP Policy for Subsequent Donation Requests will be followed and the appropriate forms (Subsequent Donation Request Form and Therapeutic T Cell Collection Prescription Form) will be submitted as required. EXCLUSION CRITERIA: RECIPIENT SUBJECTS: 1. Individuals with rapid disease progression or aggressive cancer histology who, in the opinion of the PI/Designee, require urgent therapy within 30 days in order to preserve organ function or quality of life. This restriction will not apply if there is no approved therapy with a reasonable chance of disease response, if the patient does not have access to an effective therapy and the patient appears to be eligible for an accruing CC treatment protocol or if the patient is enrolled on an NIH/CC clinical protocol, e.g., allotransplant protocol. 2. Pregnancy or lactating. Additionally, Recipient-Subjects of childbearing potential that will receive cancer treatment under this protocol must be willing to use an effective method of contraception. DONOR SUBJECTS: 1. Adult donors who are not eligible for clinical donation will not be excluded from study participation, but will only be able to donate cells for research. |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Dazzi F, Fozza C. Disease relapse after haematopoietic stem cell transplantation: risk factors and treatment. Best Pract Res Clin Haematol. 2007 Jun;20(2):311-27. Review. — View Citation
Pavletic SZ, Kumar S, Mohty M, de Lima M, Foran JM, Pasquini M, Zhang MJ, Giralt S, Bishop MR, Weisdorf D. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation. Biol Blood Marrow Transplant. 2010 Jul;16(7):871-90. doi: 10.1016/j.bbmt.2010.04.004. Epub 2010 Apr 24. Review. — View Citation
Porter DL, Alyea EP, Antin JH, DeLima M, Estey E, Falkenburg JH, Hardy N, Kroeger N, Leis J, Levine J, Maloney DG, Peggs K, Rowe JM, Wayne AS, Giralt S, Bishop MR, van Besien K. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2010 Nov;16(11):1467-503. doi: 10.1016/j.bbmt.2010.08.001. Epub 2010 Aug 10. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Count of Participants With Clinical Blood Markers of Inflammation | Count of participants with clinical blood markers of inflammation. Normal to low blood markers indicate relapse. Falling blood marker levels indicate possible imminent relapse. | up to 100 days or more following allotransplant | |
Other | Regimen-Specific Sensitivity After Allotransplant | Regimen-specific sensitivity are new or renewed sensitivity to therapies following allotransplant. | up to 100 days or more following allotransplant | |
Other | Tumor Immune Response Graft-Versus-Leukemia (GVL) | GVL is a donor anti-tumor response following transplant. | up to 100 days or more following allotransplant | |
Other | Relapse After Day 100 or Following Treatment of Graft Versus Host Disease (GVHD) | Participants who were initially in remission. | After Day 100 or Following Treatment of GVHD | |
Other | Recovery of Clinical Immunity After Allotransplant | Improved serologic responses after allotransplant. | up to 100 days or more following allotransplant | |
Primary | Immune Suppression | Biological response to agents and or treatments that can lead to bone marrow suppression/ cytopenias and sometimes death. | up to 100 days or more following transplant | |
Primary | Time to Progression After Allotransplant | Time to Progression is the time between the first day of treatment to day 100 after allotransplant. | first day of treatment to day 100 after allotransplant | |
Primary | Overall Survival | Overall Survival is the time between the first day of treatment to the day of death. | first day of treatment to the day of death | |
Primary | Days to Engraftment | Number of days for a participant to reach engraftment. | up to 100 days or more following allotransplant | |
Primary | Count of Participants With Acute Graft Versus Host Disease (GVHD) Grade 2 or More 100 Days Post Allotransplant | Acute GVHD is defined as GVHD that presents with signs and symptoms typical of acute GVHD but presenting after day 100 post allotransplant. Clinical Staging Grade 2 ((+) to (+++) Skin; (+) Liver; and (+) Gut) involvement, Grade 3 ((++) to (+++) Skin; (++ to +++) Liver; and (++ to +++) Gut) involvement, and Grade 4 ((++) to (++++) Skin; (++ to ++++) Liver; and (++ to ++++) Gut) involvement. | 100 days or more post allotransplant | |
Primary | Count of Participants With Chronic Graft Versus Host Disease (GVHD) Grade 2 or More 100 Days Post Allotransplant | Mild chronic GVHD involves only 1 or 2 organs or sites with no clinically significant functional impairment (max. score of 1 in all affected organs or sites). Moderate GVHD involves at least 1 organ or site with clinically significant but no major disability (max. score of 2 in any affected organ or site), or 3 or more organs or sites with no clinically significant functional impairment (max. score of 1 in all affected organs or sites), and a lung score of 1 will also be considered moderate chronic GVHD. Severe chronic GVHD indicates major disability caused by chronic GVHD (score of 3 in any organ or site). A lung score of 2 or greater will also be considered severe chronic GVHD. | 100 days post allotransplant | |
Primary | Count of Participants With Infection After Allotransplant | Count of Participants with Infection After Allotransplant. | up to 100 days or more post allotransplant | |
Secondary | Number of Participants With Serious and Non-Serious Adverse Events | Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. | 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Recruiting |
NCT05772000 -
Clinical Significance of Occult Central Nervous System Localization
|
||
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Active, not recruiting |
NCT03114865 -
A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06308588 -
Phase II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
|
Phase 2 | |
Recruiting |
NCT05579132 -
A Phase Ib/II Study of CN201 in Precursor B-cell Acute Lymphoblastic Leukemia
|
Phase 1/Phase 2 | |
Recruiting |
NCT04904588 -
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
|
Phase 2 | |
Terminated |
NCT02231853 -
Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections
|
Phase 1 | |
Recruiting |
NCT04969601 -
Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings
|
Phase 1/Phase 2 | |
Recruiting |
NCT06195891 -
Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome
|
Phase 1 | |
Withdrawn |
NCT02815059 -
Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone
|
Phase 1 | |
Completed |
NCT00390793 -
Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.
|
Phase 2 | |
Recruiting |
NCT05866887 -
Insomnia Prevention in Children With Acute Lymphoblastic Leukemia
|
N/A | |
Completed |
NCT00026780 -
Eligibility Screening for a NCI Pediatric Oncology Branch Research Study
|
||
Completed |
NCT04666025 -
SARS-CoV-2 Donor-Recipient Immunity Transfer
|
||
Not yet recruiting |
NCT06350994 -
Early Assessment of Cardiac Function After Treatment With CAR-T Cells
|
||
Withdrawn |
NCT04282174 -
CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies
|
Phase 2 | |
Not yet recruiting |
NCT04488237 -
Vitamin D and Methotrexate Adverse Effects
|
||
Completed |
NCT02544438 -
Study Evaluating the Safety and Efficacy of Astarabine in Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
|
Phase 1/Phase 2 |